Sionna Therapeutics, Inc. SION R2KR3KPHARMA
Company Overview
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -65.66% |
| 6 Months: | -80.02% |
| 3 Months: | -79.70% |
| 1 Month: | -85.53% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)28.94 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 85.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SION Sionna Therapeutics, Inc. R2KR3KPHARMA | 7.18 | -3.23 | $324.63M | 0.00% | -28.32% | -32.34% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating Income | -13.15M | -11.29M | -27.98M | -19.66M | -21.91M | -23.80M | -29.60M | -32.47M |
| Net Income | -11.85M | -8.55M | -25.44M | -16.48M | -18.07M | -20.28M | -26.78M | -29.89M |
| Diluted EPS | -3,840.00 | -2,710.00 | -5.67 | -0.62 | -410.00 | -0.46 | -0.60 | -0.66 |
| R&D Expense | 10.22M | 8.23M | 24.58M | 13.67M | 15.38M | 16.04M | 18.96M | 21.86M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Income | -70.56M | -88.98M |
| Net Income | -61.69M | -75.27M |
| Diluted EPS | -15.99 | -1.88 |
| R&D Expense | 57.29M | 60.26M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | - | 185.75M | 325.95M |
| Total Equity | -114.88M | -163.71M | 306.83M |
| Cash & Equivalents | - | 37.79M | 58.45M |
| Total Liabilities | - | 19.10M | 19.12M |
| Current Liabilities | - | 10.42M | 11.71M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -52.79M | -66.30M |
| Investing Cash Flow | -126.91M | -118.75M |
| Financing Cash Flow | 178.97M | 205.71M |
| Capital Expenditure | -27.00K | -377.00K |
| Free Cash Flow | -52.81M | -66.67M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | 37.7% | -24.5% |
| ROCE % | -40.2% | -28.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 21.91% | 9.91M | $58.14M |
| 2 | TPG GP A, LLC | 14.37% | 6.49M | $38.13M |
| 3 | Viking Global Investors, L.P. | 7.07% | 3.20M | $18.76M |
| 4 | Atlas Venture Life Science Advisors, LLC | 6.63% | 3.00M | $17.58M |
| 5 | Orbimed Advisors LLC. | 5.65% | 2.56M | $15.00M |
| 6 | Enavate Sciences Gp, LLC | 5.48% | 2.48M | $14.55M |
| 7 | Adage Capital Partners GP L.L.C. | 3.54% | 1.60M | $9.39M |
| 8 | JPMORGAN CHASE & CO | 3.30% | 1.49M | $8.75M |
| 9 | Blackrock Inc. | 3.26% | 1.47M | $8.66M |
| 10 | Jennison Associates LLC | 2.59% | 1.17M | $6.88M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SION
Sionna Therapeutics (SION) Stock Still Looks Cheap After The 90% Fall - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNOWpYbFhjWlBVeHlMSmw0RGhzVDIzSXlhblgwdm1TZnl0M3ZsczlDNlJwNXN4U0lDbHA0RVlhenZvT2kxV3ZSTzFpZjFzeFdvbGd3THQ2T2stTHZVUWV3UDBaSDdFRTZlZUJKdlV2T24yM2FsWFlqb1BMMUxaclZ4ME5PNUExZ1VPcDVFZW…
Sionna Therapeutics stock falls 92% after SION-719 trial failure - qz.com
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxQaWNCNXVRdTJCbzBsOUluMjYybmFGZ3BfTk00MVZkS1AydXB3Wmc0SG9kbWNMYVpsN2xncUZwbDNYVnZKdDNhVXdpU1dUc3dGMlVKUHVjZEJEbjAyWjdfWUg1R19TdkRRdjdCMWNtVFNwMmRPbWM5czVXZnRFYVUzV2ZTVmFDNWIzT1E?oc…
Why Sionna Therapeutics Stock Is Crashing 91% to a Record Low - barrons.com
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPTmxlRENQaUpRdXJSd0F3MlUwRzhDUzRNWWNBaUFQbTBrZDl0OHZId0FOengxTlVGR3JEVkV2MktXZGZidnpoTUQ1aEU0LWVlU3ZRVnhrd0xCb1hZYTJaMXlHN2NOQmhLM1IzYjFuR18xYmVkRFBkZEVuZmtzSjFZanlRWFR2SWxwODkzY0…
Sionna Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Sionna Therapeutics (SION) - PR Newswire
<a href="https://news.google.com/rss/articles/CBMilAJBVV95cUxNTWxiYzV0LVRrb0gxQ1VBMzhxcGk5bWFDMlNSbU01OTc5Q29vUEFEZjlsWnRRT21FRmVNajNQT2wwVGw3SllrT0QyYzJvUUUxMElvbC1rRGxhUlRZNTNxck9waU5YbzdKd1JBX3VkZHM5a3FkNnBXbkNWeXhaOUFJT0JTRGw5TlhFX3ZHMF…
SION Stock On Track For Worst Day Ever After 90% Drop — What’s Driving The Selloff? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxON2tTcnJ4a2MtbWo2QzFTbGt3NXVXOXZnZmRoVG9xNGZOSGRmS3p2Mk1aT09XTmdIbElKWnpsQnNwOGJDdWxTa3h6LTUxR3U4ZzU4Q2xvdEZXbHVaanVRdTdRM3BpV2lIYlhpMHVaUnlKRF9tbmtqZmdBX0ZNWm93NHN1UTQxNHB5aEhwSi…
$SION stock is down 9% today. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPMy1mbzBDY1ppdlIwVmZkNlJzV0ZjNUxNbWFmVTlEMWFKSlVnQ3RWR1FSODQ1Rmpaa3NUVGNhUnpZSUp4Y2dCZExmVVBPLXZndUZXeFpNamkybER4dHkzUWljdGVIMVE2WlhXSnlOSDJXWHV6STZhQnY4RWtUeDJJWjJMODRuNkNERlp0V3…
SION — Frequently Asked Questions
What is the current share price of Sionna Therapeutics, Inc. (SION)?
As of 2026-09-07 16:24 PDT, Sionna Therapeutics, Inc. (SION) trades at $7.18 on NasdaqGM. Its 52-week range is $4.50 to $51.04.
What is the market capitalisation of SION?
Sionna Therapeutics, Inc. (SION) has a market capitalisation of $324.63M on NasdaqGM.
What is the P/E ratio of SION?
SION trades at a trailing price-to-earnings (P/E) ratio of -3.23. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 7.44.
What is the return on equity (ROE) of SION?
SION has a return on equity (ROE) of -32.34%. Its return on capital employed (ROCE) is -28.32%.
Is SION a good stock to buy?
This page provides a data-driven analysis of Sionna Therapeutics, Inc. (SION), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.